June 21, 2018 Leveraging ADAPT Biotargeting System would have significantly increased the probability of success Data presented at the ESMO World Congress on Gastrointestinal Cancer 2018 IRVING, Texas, June 21, 2018 /PRNewswire/ — Caris Life Sciences®, a leading innovator in molecular science focused on
Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study
